CLDI (Calidi Biotherapeutics) Buildings And Improvements: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDI Calidi Biotherapeutics Inc CLDI
12 GF Score
Price $1.52
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics Buildings And Improvements?

Calidi Biotherapeutics CLDI -6.75% 12 Buildings And Improvements is $0.00 Mil as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Calidi Biotherapeutics Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Buildings And Improvements Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLDI
12GF Score
Calidi Biotherapeutics Inc CLDI
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Calidi Biotherapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $0.00 Mil mean?
Calidi Biotherapeutics (CLDI) has a Buildings And Improvements of $0.00 Mil as of Mar. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' Buildings And Improvements too high?
Calidi Biotherapeutics' current Buildings And Improvements is $0.00 Mil. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Buildings And Improvements compare to BBLG and CDT?
Calidi Biotherapeutics' Buildings And Improvements of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current Buildings And Improvements is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Buildings And Improvements of $0.00 Mil. The current Buildings And Improvements is $0.00 Mil. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Buildings And Improvements is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score

Get the complete analysis for CLDI

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.52
Price